| Nicox–GHO Capital: investment, 201607– acquisition €26m with €9m cash + €12m shares+loan notes + €5m milestones of Nicox commercial operations by GHO |
2016-07-05 |
| Global Bioenergies–Germany (govt): grant, 201607–201709 BMBF grant €400k for developm of renewable gasoline additives |
2016-07-01 |
| Denali Therapeutics–SEVERAL: investment, 201606 financing round Series B $130m led by Baillie Gifford + incl all founding plus new investors |
2016-06-30 |
| PBM Capital–Lonza: investment, 201606 acquisition of Triangle Research Labs LLC from PBM Capital Group |
2016-06-30 |
| Charles River–Caprotec: CCMS technology, 201606 collab use of CCMS tech to identify protein targets relevant for phenotypic drug candidate responses |
2016-06-29 |
| Evotec–Ellersbrook: investment, 201606– Ellersbrook will invest in Evotec’s internal TargetNASH programme |
2016-06-29 |
| Evotec–Genedata: bioinformatics, 201606– supply license Evotec using Genedata Screener now in HTS + HCS |
2016-06-28 |
| IntelliCyt–Sartorius: investment, 201606 acquisition for $90m in cash incl $5m in future tax savings |
2016-06-28 |
| Novartis–Xencor: antibody technology, 201606– collab + license $150m upfront + cost-sharing developm of biospecific antibodies for cancer |
2016-06-28 |
| Storm Therapeutics–Merck (DE): investment, 201606 financing round Series A totalling £12m incl investor Merck Ventures |
2016-06-28 |
| Storm Therapeutics–SEVERAL: investment, 201606 financing round Series A £12m with CIC + Merck Ventures + Pfizer Venture + Touchstone Innovations |
2016-06-28 |
| Cosmo Pharmaceuticals–Paion: remimazolam, 201606– license excl €10m upfront + €42.5m milestones + royalties for developm + commercialisation in US |
2016-06-24 |
| CRISPR Therapeutics–SEVERAL: investment, 201606 financing round Series B additional $38m closing from new investors |
2016-06-24 |
| Paion–Cosmo Pharmaceuticals: investment, 201606 investment as part of license agreem w Cosmo becoming largest shareholder holding 9.09% |
2016-06-24 |
| IFM Therapeutics–Abingworth: investment, 201606 financing round Series A totalling $27m incl lead investors Atlas Venture + Abingworth |
2016-06-22 |
| IFM Therapeutics–Atlas Venture: investment, 201606 financing round Series A totalling $27m incl lead investors Atlas Venture + Abingworth |
2016-06-22 |
| IFM Therapeutics–Novartis: investment, 201606 financing round Series A totalling $27m incl co-investor Novartis |
2016-06-22 |
| IFM Therapeutics–SEVERAL: investment, 201606 financing round Series A $27m led by Atlas Venture + Abingworth + incl Novartis |
2016-06-22 |
| Qiagen–Barclays: financial services, 201606 supply financial advisor to Qiagen with regard to offer for Exiqon AS |
2016-06-22 |
| MetaSUB project–Qiagen: genomic sample preparation, 201606– collab project using Qiagen sample tech + library prepration workflows |
2016-06-21 |
| F2G Ltd–SEVERAL: investment, 201606 financing round $60m led by Sector Asset Management |
2016-06-20 |
| Allecra Therapeutics–Delos Capital: investment, 201606 financing round Series B totalling €22m incl new + lead investor Delos Capital |
2016-06-16 |
| Allecra Therapeutics–Forbion: investment, 201606 financing round Series B totalling €22m incl returning co-investor FCF II Co-Invest I fund |
2016-06-16 |
| Allecra Therapeutics–SEVERAL: investment, 201606 financing round Series B €22m led by new investor Delos Capital |
2016-06-16 |
| Gilde Investment–SEVERAL: investment, 201606 final close of €250m Gilde Healthcare IV fund incl cornernstone investor Philips |
2016-06-14 |
| Univ Manchester–Danaher: mass spectrometer, 201606 supply Sciex Lipidyzer Platform to Stoller Centre |
2016-06-13 |
| Bluebird Bio–Lonza: contract manufacturing, 201606– collab long-term commercial manufacturing of Lenti-D + LentiGlobin drug products by Lonza Houston |
2016-06-09 |
| CRISPR Therapeutics–Anagenesis: cell therapy, 201606– strategic collab + ww excl license to P2MC technology for cell therapy for muscle diseases |
2016-06-08 |
| Sony–Stratec: investment, 201606–201607 acquisition €30m 100% of Sony DADC BioSciences business by Stratec |
2016-06-08 |
| F-Star–CMC Biologics: contract manufacturing, 201606– service manufacturing of mAb² bispecific antibodies by CMC Biologics |
2016-06-07 |
| Dr. Falk Pharma–Cosmo Pharmaceuticals: antibiotic, 201606– license existent for Rifamycin SV MMX for EU + Australia |
2016-06-06 |
| Pieris–SEVERAL: investment, 201606 private placement $16.5m w 8.18m units (shares + warrants) at $2.015/unit led by BVF Partners |
2016-06-03 |
| Grünenthal–AstraZeneca: lesinurad, 201606– license excl for Europe + Latin America to Zurampic + fixed dose combi of lesinurad + allopurinol |
2016-06-02 |
| Thermo Fisher–908 Devices: sample separation technology, 201606 collab integration of ZipChip microfluidics separation with Orbitrap MS systems |
2016-06-02 |
| Boehringer–Harvard Univ: drug research, 201606– collab research alliance 3y €na for novel treatments for severe fibrotic diseases |
2016-06-01 |
| Emperra–Germany (govt): business development, 201606– supply service support in US with German Accelerator Life Sciences programme |
2016-06-01 |
| ERS Genomics–MacDougall Biomedical Communications: public relations, 201606 service existent by MacDougall |
2016-06-01 |
| TxCell–Univ Lübeck: cell therapy, 201606– collab €na developm of CAR-Treg cells to treat bullous pemphigoid with LIED |
2016-06-01 |
| Hyglos–Mérieux: investment, 201605 acquisition 100% of Hyglos by bioMérieux for €24m phased over 3 years |
2016-05-31 |
| Link Health–4SC: cancer drug, 201605– collab license + developm partnership for 4SC-205 in Greater China |
2016-05-31 |
| Sividon Diagnostics–Myriad: investment, 201605 acquisition for €35m upfront + €15m milestones |
2016-05-31 |
| Aleva Neurotherapeutics–SEVERAL: investment, 201605 financing round Series C $18m incl $5m from strategic lead investor Greatbatch Inc |
2016-05-27 |
| Qiagen–Therawis: molecular companion diagnostics, 201605– license + co-developm predictive oncology tests w initial project using PITX2 assay |
2016-05-25 |
| Axela–Scienion: print/spotting technology, 201605– collab developm + marketing of production systems + services for diagnostics + research |
2016-05-24 |
| Epigenomics–SEVERAL: investment, 201605 private placement €6.8m w 1.436m new shares at €4.76/share led by BioChain (55%) |
2016-05-24 |
| MorphoSys–Univ Texas: antibody cancer drug, 201605– collab strategic alliance r+d using Ylanthia technology with MD Anderson ORBIT unit |
2016-05-24 |
| Xenikos–MC Services: public relations, 201605 service existent for Xenikos BV by MC Services AG Düsseldorf |
2016-05-24 |
| Boehringer–BioMed X: pharma research, 201605– collab new BioMed X research group to discover new treatm options for psychiatric diseases |
2016-05-23 |
| Univ Birmingham–Thermo Fisher: mass spectrometer, 201605 supply one Orbitrap Elite MS system w nanoLC + 2D-LC + Advion Triversa Nanomate at PCB |
2016-05-23 |
| Univ Birmingham–Thermo Fisher: mass spectrometer, 201605 supply Q Exactive Plus MS system at Birmingham Metabolomics Training Centre |
2016-05-23 |
| Univ Birmingham–Thermo Fisher: mass spectrometer, 201605 supply three Q Exactive Focus MS systems w Ultimate3000 RSLC UHPLC systems at PCB |
2016-05-23 |
| Univ Birmingham–Thermo Fisher: mass spectrometer, 201605 supply two Quantiva triple quad MS systems w Ultimate3000 RSLC UHPLC systems at PCB |
2016-05-23 |
| Univ Birmingham–United Kingdom (govt): grant, 201411–201605c award £8m for new Phenome Centre Birmingham from MRC + 4 instrument firms + the Univ |
2016-05-23 |
| Monsanto–Bayer: investment, 201605– acquisiton unsolicited $66b all-cash offer $128/share by Bayer |
2016-05-19 |
| Medigene–BioNTech: cell therapy, 201605– supply + collab process developm to produce TCR-modified T cells by Eufets GmbH |
2016-05-18 |
| Bayer–ERS Genomics: CRISPR technology, 201605– license €na to patents for certain cross-divisional applications in Bayer’s core strategic areas |
2016-05-17 |
| NousCom–Life Sciences Partners: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
| NousCom–SEVERAL: investment, 201605 financing round Series A €12m co-led by LSP + Versant Ventures |
2016-05-17 |
| NousCom–Versant Ventures: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
| Caribou Biosciences–Novartis: investment, 201605 financing round Series B totalling $30m incl existing investor Novartis |
2016-05-16 |
| Caribou Biosciences–SEVERAL: investment, 201605 financing round Series B $30m from new + existing investors |
2016-05-16 |
| EndoStim–Gimv: investment, 201605 financing round Series D totalling $25m incl $2.7m from Gimv Health & Care |
2016-05-12 |
| EndoStim–SEVERAL: investment, 201605 financing round Series D $25m led by Endeavour Vision + incl Santé Ventures + Gimv + Wellington Partners et al |
2016-05-12 |
| Boehringer–Max Planck: CNS drug, 201605– Boehringer acquires option for excl rights to new schizophrenia lead compound from LDC |
2016-05-11 |
| Bayer–BioNTech: mRNA technology, 201605– collab €na developm mRNA vaccines + therapeutics for animal use |
2016-05-10 |
| BioNTech–Bayer: investment, 201605 investment €na by BLSC in connection with animal health mRNA collaboration |
2016-05-10 |
| Novimmune–SEVERAL: investment, 201605 financing round CHF30m from existing shareholders |
2016-05-10 |
| AC Immune–SEVERAL: investment, 201605 private financing round Series E CHF42.7m |
2016-05-09 |
| Expedeon–Genetrix (ES): investment, 201605–201608 acquisition of Expedeon Holdings Ltd by Sygnis AG for €1.7m cash + na shares |
2016-05-09 |
| Genetrix (ES)–SEVERAL: investment, 201605–201607 capital increase Sygnis AG €5.3m w 3m rights offering + 1.8m shares private placement €1.1/share |
2016-05-09 |
| LabCorp–Epigenomics: molecular diagnostics cancer test, 201605– distribution LabCorp to offer Epi proColon test in the US |
2016-05-09 |
| Alrise Biosystems–Creathor Ventures: investment, 201605 existent Alrise listed as current investment on web site of Creathor |
2016-05-06 |
| Ayoxxa–Creathor Ventures: investment, 201605 existent Ayoxxa listed as current investment on web site of Creathor |
2016-05-06 |
| CAP-CMV GmbH–Creathor Ventures: investment, 201605 existent CAP-CMV listed as current investment on web site of Creathor |
2016-05-06 |
| Caprotec–Creathor Ventures: investment, 201605 existent Caprotec listed as current investment on web site of Creathor |
2016-05-06 |
| Cevec–Creathor Ventures: investment, 201605 existent Cevec listed as current investment on web site of Creathor |
2016-05-06 |
| Chundsell Medicals–Creathor Ventures: investment, 201605 existent Chundsell listed as current investment on web site of Creathor |
2016-05-06 |
| Cube Biotech–Creathor Ventures: investment, 201605 existent Cube Biotech listed as current investment on web site of Creathor |
2016-05-06 |
| Klara–Creathor Ventures: investment, 201605 existent Klara listed as current investment on web site of Creathor |
2016-05-06 |
| Phenex–Creathor Ventures: investment, 201605 existent Phenex listed as current investment on web site of Creathor |
2016-05-06 |
| Sirion Biotech–Creathor Ventures: investment, 201605 existent Sirion Biotech listed as current investment on web site of Creathor |
2016-05-06 |
| Sividon Diagnostics–Creathor Ventures: investment, 201605 existent Sividon listed as current investment on web site of Creathor |
2016-05-06 |
| Euticals–Albany Molecular: investment, 201604–201607 acquisition €315m in cash + stock + a seller note of Prime European Therapeuticals SpA by AMRI |
2016-05-05 |
| TU Munich–Werner Siemens Foundation: grant, 201605– donation €11.5m to promote synthetic biotechnology in new TUM School of Bioengineering |
2016-05-04 |
| Vaximm–MC Services: public relations, 201605 service existent for Vaximm by MC Services AG |
2016-05-04 |
| Ideaya Biosciences–Novartis: investment, 201605 financing round Series A totalling $46m including investor Novartis Institute of Biomedial Research |
2016-05-03 |
| Ideaya Biosciences–SEVERAL: investment, 201605 financing round Series A $46m from 5AM Ventures + Canaan Ventures + NIBR et al |
2016-05-03 |
| IMS Health–Quintiles: investment, 201603–201610 merger $10.4b into Quintiles IMS w former IMS owners holding 51.4% after merger |
2016-05-03 |
| Eppendorf–Bio-ITech: bioinformatics, 201605 collab product integration of eLabJournal ELN with Eppendorf instruments shown at Analytica 2016 |
2016-05-02 |
| PRECIOUS project (2)–EU (govt): grant, 201605–202104 Horizon 2020 grant €8.3m to develop cancer immuntherapeutic nanomedicine led by Radboud Univ |
2016-05-01 |
| Roche–Evotec: drug discovery services, 201605–201904 collab extension for 3 years discovery small molecule drugs for Genentech |
2016-05-01 |
| 4SC–BioNTech: investment, 201604 acquisition €650k of all key operating assets + employees of 4SC Discovery GmbH by new BioNTech Small Molecules GmbH |
2016-04-29 |
| Glycotope–Consilium: public relations, 201604 service existent by CSC |
2016-04-29 |
| Novartis–BioQ Pharma: pharmaceutical, 201604– expansion excl license + supply agreem for one more for ready-to-use infusion product to Sandoz in US |
2016-04-28 |
| Sayre Therapeutics–Oncgnostics: cervical cancer test, 201604– distribution excl of GynTect test in India et al by Sayre Therapeutics Pvt Ltd |
2016-04-28 |
| Bentekk–Hamburg (govt): investment, 201604 seed funding 6-digit €na from HTGF + Innovationsstarter Fonds Hamburg |
2016-04-27 |
| Bentekk–High-Tech Gründerfonds: investment, 201604 seed funding 6-digit €na from HTGF + Innovationsstarter Fonds Hamburg |
2016-04-27 |
| Bentekk–SEVERAL: investment, 201604 seed funding 6-digit €na from HTGF + Innovationsstarter Fonds Hamburg |
2016-04-27 |
| Boehringer–VTU: recombinant protein production, 201604– collab ww expansion of agreem for Pichia pastoris technology + incl E coli platform |
2016-04-27 |
| UBS–MPM Capital: fund management, 201604– collab MPM is advisor to new $471m UBS Oncology Impact Fund |
2016-04-27 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 28 29 30 31 
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
